Clinical Trial Update: SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients [Phase 2]

View source ↗

Summary

Phase II clinical trial update for SA55 Injection in mild/moderate COVID-19 patients is listed as Phase 2 with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infection of Upper Respiratory Tract Caused By 2019-ncov

Drugs mentioned

• SA55 Injection

Snippet

Sponsor: Sinovac Life Sciences Co., Ltd. | Conditions: Infection of Upper Respiratory Tract Caused by 2019-nCoV | Phase 2 | Status: UNKNOWN